Denali Therapeutics (DNLI) to Release Earnings on Tuesday

Denali Therapeutics (NASDAQ:DNLI) is anticipated to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Denali Therapeutics to post earnings of ($0.75) per share and revenue of $12.75 million for the quarter.

Denali Therapeutics Price Performance

DNLI stock opened at $20.75 on Friday. Denali Therapeutics has a 1-year low of $14.56 and a 1-year high of $33.33. The firm has a fifty day moving average price of $21.62 and a two-hundred day moving average price of $24.69. The firm has a market cap of $2.99 billion, a price-to-earnings ratio of -7.52 and a beta of 1.43.

Insider Buying and Selling

In related news, CEO Ryan J. Watts sold 29,266 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $20.22, for a total value of $591,758.52. Following the completion of the sale, the chief executive officer now owns 260,721 shares of the company’s stock, valued at $5,271,778.62. This represents a 10.09 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Vicki L. Sato sold 3,080 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares of the company’s stock, valued at $2,257,778.16. The trade was a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 47,940 shares of company stock valued at $973,442 over the last 90 days. 7.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several research firms have weighed in on DNLI. HC Wainwright lowered their target price on shares of Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Denali Therapeutics in a research note on Tuesday, February 11th. They set a “buy” rating and a $31.00 target price for the company. Jefferies Financial Group upped their price target on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research report on Friday, November 1st. Robert W. Baird initiated coverage on shares of Denali Therapeutics in a research report on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price target for the company. Finally, The Goldman Sachs Group lowered their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Two investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Denali Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $37.42.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.